Furthest along
9 approved
1 in Phase 3
Drugs
23
in active trials · 104 in all
Trials
33 active
308 since 2021
Drugs23
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | 22 Jan 2027Phase 1 trial completes | |||
| Next date | 22 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes and 1 more | ||||
| Open drug page | |||||
Mineralocorticoid receptor antagonist |
Approved | 10 Apr 2027Phase 3 trial completes | |||
| How it works | Blocks aldosterone | ||||
| Next date | 10 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Kidney Disease, Proteinuria and 3 more | ||||
| Open drug page | |||||
— |
Approved | 30 Jul 2027Phase 3 trial completes | |||
| Next date | 30 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Cancer, Non-metastatic Castration-resistant Prostate Cancer and 2 more | ||||
| Open drug page | |||||
Transthyretin stabilizer |
Approved in the EU | 17 Sep 2027Phase 4 trial completes | |||
| Next date | 17 Sep 2027 · Phase 4 trial completes | ||||
| Also tested for | Transthyretin Amyloid Cardiomyopathy | ||||
| Open drug page | |||||
HER2/EGFR inhibitor |
Approved | 28 Oct 2027Phase 3 trial completes | |||
| Next date | 28 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | HER2 Mutation, Advanced Non-small Cell Lung Cancer and 3 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 27 Apr 2028Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 27 Apr 2028 · Phase 2 trial completes | ||||
| Also tested for | Solid Malignant Tumors | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | — | |||
| How it works | Blocks a kinase | ||||
| Also tested for | Solid Tumors Harboring NTRK Fusion | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | ||||
| Open drug page | |||||
Soluble guanylate cyclase stimulator |
Approved | — | |||
| How it works | Boosts a chemical signal (cGMP) that relaxes blood vessels and eases strain on the heart | ||||
| Also tested for | Hypertension, Pulmonary | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Obstructive Hypertrophic Cardiomyopathy | ||||
| Open drug page | |||||
— |
Phase 2 | 29 Nov 2027Phase 2 trial completes | |||
| Next date | 29 Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Alport Syndrome | ||||
| Open drug page | |||||
— |
Phase 2 | 15 Jun 2029Phase 2 trial completes | |||
| Next date | 15 Jun 2029 · Phase 2 trial completes | ||||
| Also tested for | Parkinson Disease | ||||
| Open drug page | |||||
— |
Phase 1/2 | 18 Jun 2029Phase 1/2 trial completes | |||
| Next date | 18 Jun 2029 · Phase 1/2 trial completes | ||||
| Also tested for | MTAP-deleted Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 2 | 16 May 2030Phase 2 trial completes | |||
| Next date | 16 May 2030 · Phase 2 trial completes | ||||
| Also tested for | Atrial Fibrillation | ||||
| Open drug page | |||||
— |
Phase 1 | 25 Dec 2026Phase 1 trial completes | |||
| Next date | 25 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Sepsis, Coagulopathy and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Apr 2027Phase 1 trial completes | |||
| Next date | 30 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
Guanylate cyclase activators and stimulator |
Phase 1 | 7 May 2027Phase 1 trial completes | |||
| How it works | Boosts a chemical signal (cGMP) that relaxes blood vessels and eases strain on the heart | ||||
| Next date | 7 May 2027 · Phase 1 trial completes | ||||
| Also tested for | Stable Coronary Artery Disease | ||||
| Open drug page | |||||
— |
Phase 1 | 8 Jun 2027Phase 1 trial completes | |||
| Next date | 8 Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | Metastatic Castration-resistant Prostate Cancer | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Nov 2027Phase 1 trial completes | |||
| Next date | 30 Nov 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors Harboring KRAS G12C Mutation | ||||
| Open drug page | |||||
— |
Phase 1 | 26 Nov 2028Phase 1 trial completes | |||
| Next date | 26 Nov 2028 · Phase 1 trial completes | ||||
| Also tested for | Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 81 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev